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Abstract: Radiation-induced lung injury (RILI), including acute radiation pneumonitis and chronic
radiation-induced lung fibrosis, is the most common side effect of radiation therapy. RILI is a
complicated process that causes the accumulation, proliferation, and differentiation of fibroblasts
and, finally, results in excessive extracellular matrix deposition. Currently, there are no approved
treatment options for patients with radiation-induced pulmonary fibrosis (RIPF) partly due to the
absence of effective targets. Current research advances include the development of small animal
models reflecting modern radiotherapy, an understanding of the molecular basis of RIPF, and the
identification of candidate drugs for prevention and treatment. Insights provided by this research
have resulted in increased interest in disease progression and prognosis, the development of novel
anti-fibrotic agents, and a more targeted approach to the treatment of RIPF.
Keywords: radiation; lung fibrosis; animal models; antifibrotic; therapeutic targets
1. Introduction
Radiation therapy (RT) is performed in about 50% of all cancer patients at least once during
their treatment course. Recently, with the development of computer and mechanical engineering,
it has become increasingly important through effective treatment. Clinical RT involves irradiation
with high radiation doses to remove tumors. Surrounding normal tissue adjacent to the tumor is
prone to side-effects. The most common side effects after ionizing radiation (IR) treatment of thoracic
tumors are pneumonitis and pulmonary fibrosis (PF). While pneumonitis occurs early following
treatment and may be reversible, PF is considered to be irreversible delayed toxicity [1]. Pneumonitis
can occur in as many as 50% of lung cancer patients, and rates of PF can be as high as 70–80%
in high-dose regions of the lung [2]. Although it affects fewer people than idiopathic pulmonary
fibrosis (IPF) per se, similar pathological changes are seen in a minority of adult cancer survivors
exposed to lung irradiation. Currently, there are no approved treatment options for patients with
radiation-induced PF (RIPF), which may be mediated by the absence of effective targets. However,
regimens for IPF, such as pirfenidone and nintedanib, help to reduce clinical exacerbations that affect
pulmonary function [3,4]. In this review, to emphasize the importance of small animal models, we first
described the characteristics of radiation-induced lung injury (RILI) including radiation pneumonitis
and RIPF. In addition, we discussed the pathological mechanisms of RIPF including the cytokine
secretion, and the epithelial and endothelial-to-mesenchymal (EMT/EndMT) process. Lastly, we also
described the antifibrotic agents used in the clinic or under the investigations.
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2. Radiation-Induced Lung Injury (RILI)
When IR passes through the lung tissue, energy not only directly induces double-strand break
(DSBs) of the DNA molecule, but also has sufficient strength to hydrolyze water and other molecules.
This hydrolysis produces reactive oxygen species (ROS), which can interact with DNA and other
cellular components of extracellular matrix (ECM) [5]. Most DNA damage is repaired, but incorrect
repair can lead to cell deficiency and apoptosis for a much longer time, and may even initiate a strong
immune response even before tissue damage is induced [6]. IR exposure can lead to apoptosis of
epithelial and endothelial cells within hours and this apoptosis has been experimentally demonstrated
to occur in the lung parenchyma after injury [7]. Moreover, ROS can also be produced by cascades of
pro-inflammatory cytokines, and the release of cytokines and other products of activated transcription
factors play an important role in the progression of RILI [8] (Figure 1).
Figure 1. Schematic representation showing distinct and overlapping stages of radiation-induced lung
injury. Radiation-induced lung injury consists of overlapping and highly coordinated stages of acute
radiation response, inflammation, proliferation, and fibrosis. After lung injury, ionizing radiation
induces reactive oxygen species (ROS) induction, DNA damage, and vascular damage. Damaged
epithelial cells and/or endothelial cells release inflammatory mediators that recruit immune cells.
The recruited immune cells secrete profibrotic cytokines such as IL-1β, TNF, IL-13, and TGF-β. Secreted
cytokines amplify the inflammatory response and trigger fibroblast proliferation and recruitment,
which eventually culminates in fibrotic changes. Abbreviation: ROS: Reactive oxygen species, IL-1β:
Interleukin 1 beta, TNF: Tumor necrosis factor, IL-13: Interleukin 13 beta, TGF-β: Transforming growth
factor-β, EMT: Epithelial to mesenchymal transition, EndMT: Endothelial to mesenchymal transition,
ECM: Extracellular matrix
2.1. Radiation Pneumonitis
Radiation pneumonitis as an acute reaction occurs within 4–12 weeks after RT. The acute
pneumonitis stage is characterized by recruiting various immune cells into the alveolar space, thickening
the alveolar septum, and destroying the integrity of the alveoli. At this time, infiltration of myeloid
and lymphoid cells occurs, which results in lung inflammation and edema of alveolar interstitium
and the air space [9]. In the lung alveoli, which is the end of the respiratory tree, there are two
types of alveolar epithelial cells (AECs or pneumocytes) known as AECI and AECII. In addition to
epithelial cells, alveolar macrophages are present in the alveolar space, which are essential for tissue
homeostasis, early pathogen recognition, and the initiation of local immune responses and resolution
of inflammation. Resident fibroblasts are the most prominent cell type in the alveolar interstitium.
Under certain pathological situations, resident fibroblasts can be activated and transformed into
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myofibroblasts. Myofibroblasts are the main effector cells of tissue fibrosis [10–12]. When ACEI
undergoes apoptosis or necrosis, depletion of the basement membrane occurs, which is followed by
hyperplasia of ACEII. However, the accelerated proliferation of ACEII inhibits the ability of lung
surfactants production, which causes surface tension to be lost. This is followed by edema and lethargy
of lung tissue [13]. Edema increases vascular permeability, which causes plasma proteins and fibrin-rich
exudate to leak into the alveolar space. Radiation pneumonitis without specific treatment remains
a major dose-limiting complication in patients. The current treatments including steroids, diuretics,
hormones, enzymes, and antioxidants are still non-specific and symptomatic. If pulmonary damage
is so extensive that homeostasis cannot be restored by any repair mechanisms, the integrity of the
alveolar-capillary barrier begins to decompose at certain points where it does not recover. This makes
RIPF worse due to inadequate regeneration and subsequent processing of lung tissue (Figure 2).
Figure 2. Pathobiology of radiation pneumonitis and radiation-induced lung injury. (A) Healthy
alveolus. The epithelium, which is the outer layer of the alveoli, consists of two types of cells (type 1 and
type 2 cells). Type 1 alveolar cells cover 95% of the alveolar surface and constitute an air-blood barrier.
Type 2 alveolar cells are smaller and are responsible for the production of surfactants that coat the
inside of each alveolus when inhaling and breathing. (B) Radiation pneumonitis is inflammation of the
lungs caused by radiotherapy. Chronic pneumonitis can cause scarring of the lungs called pulmonary
fibrosis. (C) Pulmonary fibrosis. General changes seen in interstitial lung disease. There is proliferation
of interstitial fibroblasts and recruitment of fibrocytes into the interstitium (extracellular matrix (ECM)).
These cells begin secreting components of the ECM such as collagen and other fibers. Cells also convert
to myofibroblasts, which produce more ECM. Prolonged fibroblast activity leads to fibrosis, which is a
hallmark of interstitial lung disease and restrictive lung patterns. Abbreviation: EMT: Epithelial to
mesenchymal transition; EndMT: Endothelial to mesenchymal transition; ECM: Extracellular matrix
2.2. Radiation-Induced Pulmonary Fibrosis
RIPF occurs at an irreversible stage more than six months after irradiation. The characteristic
RIPF is the accumulation of fibroblasts and myofibroblasts, causing extensive production of collagen,
infiltration of inflammatory cells, and remodeling of ECM. This is followed by fibrosis of the alveolar
septum, which, in turn, leads to extensive occlusion of the alveoli. RIPF is characterized by the
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accumulation of the ECM protein, which lowers the ability of the lungs to exchange oxygen. In response
to IR, resident lung fibroblasts can differentiate into myofibroblasts, which can secrete ECM proteins.
Activated myofibroblasts contribute to fibrogenesis. Therefore, inhibiting IR-induced myofibroblast
differentiation is an important therapeutic strategy for preventing fibrosis [14,15]. IR activates
fibroblasts/myofibroblasts, which leads to incorrect regulation and exaggerated repair processes,
and eventually fibrosis [16]. Epithelial-mesenchymal transition (EMT) is one of the processes that
causes lung fibrosis, which is activated by IR, but may also be involved in other pulmonary processes
such as embryonic development [17] and tumorigenesis [18]. The major cytokine involving the EMT
process is transforming growth factor-β (TGF-β). TGF-β signaling initiates the trans-differentiation
of epithelial cells into activated myofibroblasts [17]. The main role of cells undergoing EMT is the
synthesis and deposition of ECM proteins.
3. Animal Models of RIPF
3.1. Animal Models That Mimic Conventional RT
Classical studies using whole thorax irradiation have provided important information about the
pulmonary IR responses of different rodent strains and defined dose thresholds for lung toxicities.
Susceptibility to fibrosis to IR is genetically based in mice, and, most notably, C3H/HeJ and CBA/J
mice are resistant to IR-induced fibrosis in comparison with the more susceptible C57BL/6 strain [19].
C3H/He mice are used as a classical model to develop early-stage pneumonitis, but do not develop
fibrosis below a single dose of 20 Gy by 12–20 weeks. In contrast, 20 Gy in C57BL/6 mice are sufficient
to induce fibrosis, while other strains are intermediate between these extremes [20]. To avoid a systemic
complication, RT that usually delivers thorax-limited IR is applied and, in this case, fibrosis takes
up to 24 weeks [21,22]. During the pulmonary fibrosis, inflammatory responses affect the severity of
lung remodeling but is rarely associated with mortality [19]. The pathology of RIPF is believed to
involve ROS-mediated DNA damage and TGF-β production [23]. The introduction of the small animal
irradiator significantly improves the precision and accuracy of the dose delivery to the mice, so that
more clinically relevant dose and fractionation schedules could be experimentally achieved. When
using a small animal irradiator targeting a 10% to 30% sub-volume of the lungs or the near whole lung,
representative examples of the dose distribution is shown in Figure 3. Recently, only a small number of
published studies focused on RIPF have aimed to improve understanding of the major biological and
physical factors supporting the lung’s IR response as preclinical technology advances using a small
animal irradiator. This suggests that, as the preclinical techniques advance, there are many challenges
and opportunities to understand the biological and physical factors of the lung’s IR response. Fibrosis
developed in response to application of 20 Gy to the entire left lung of C57BL/6 mice, and a significant
amount of lung fibrosis was observed at 12 months after IR. Collagen deposition was observed at three
months after IR with peak induction at 12 months. Fibrosis-related genes identified revealed several
differences between 20 Gy IR and 75–90 Gy SBRT (stereotactic body radiation therapy)-mimicking
irradiation, which suggested different molecular mechanisms of a low dose whole lung irradiation and
a high dose focal irradiation in developing lung fibrosis [24].
3.2. Animal Models to Mimic Stereotactic Body Radiation Therapy (SBRT)
More sophisticated conformal RT techniques such as intensity-modulated RT (IMRT), volumetric
arc RT (VMAT), stereotactic body radiation therapy (SBRT), and stereotactic radiosurgery (SRS) have a
lower RILI incidence than standard 3D conformal RT. This can be due to the increased precision of
IR delivery to the tumor, which, thereby, protects the surrounding normal tissue. Moreover, due to
the diversity of the technology, it is possible to guide the intensity and direction of the radiation
beam by taking into account the anatomy, breathing pattern, and organ motion of the patient. All of
these modalities are expected to lower the volume of lung irradiation and the irradiation dose while
maintaining millimeter-range accuracy. Moreover, SBRT is the standard of care for patients with
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medically inoperable stage I NSCLC (Non-small-cell lung carcinoma) [25]. The steep dose gradient and
sharp dose fall-off achieved with SBRT substantially reduces treatment volume, and, thereby, reduces
the dose to surrounding normal tissues. However, based on published data, the rate of symptomatic
IR pneumonitis ranges from 0–49%. The rate of RILI, which can continue to evolve one year after
SBRT, is still 70% to 80% in high-dose regions [26]. A mouse model simulating clinical SBRT in terms
of ablative dose delivery in a few fractions has been used to show the induction of pulmonary fibrosis
using image-guided high-dose-per-fraction irradiation system [27]. Fibrosis-related gene expression in
the 90 Gy SBRT-mimicking model was different from that of the 20 Gy conventional RT model [24].
In the SBRT mimicking model, no difference in fibrosis progression between radiosensitive C57BL/6
and radioresistant C3H mice was detected [28]. Because fibrosis development was rapidly induced in
this model (4–6 weeks) compared to the conventional RT animal model (6–12 months), it may be a
good preclinical model to evaluate anti-fibrotic drugs.
Figure 3. General comparison of conventional and stereotactic SBRT-mimicking RIPF models.
(A) Summary of conventional and SBRT-mimicking RIPF models. In the conventional RIPF model,
a large volume of the lung is irradiated with a relatively low dose of radiation, and an abundance
of radiobiological research data has been generated. In contrast, the SBRT-mimicking RIPF model
mimics modern radiotherapy whereby there is local irradiation with high radiation doses. (B) Both
the dose and fractionation of radiation contribute to the severity of radiation fibrosis. RIPF is known
to be accelerated with a higher radiation dose per fraction. Therefore, the radiation dose is very
important for the development of RIPF. Abbreviations: SBRT: Stereotactic body radiation therapy; RIPF:
Radiation-induced pulmonary fibrosis
4. Characteristics of RIPF
The pathological mechanism of RIPF is complex and involves numerous cell types. Thorax
IR induces delayed damage to resident lung cells, which, primarily, leads to apoptosis of bronchial
epithelial cells and loss of barrier function [29]. Recent studies have shown that damaged epithelial cells
can become a source of myofibroblasts called EMT/EndMT (Epithelial and endothelial-to-mesenchymal
transition) [30–32]. Myofibroblasts are known to play a central role in the pathogenesis of RIPF
because these cells produce collagens, fibronectins, and other matrix molecules [33–35]. Moreover,
thorax IR has been shown to induce recruitment of various immune cells into the lungs. After IR
exposure, the expression of Th2-related cytokines increased, and the expression of Th1-related cytokines
decreased. Thereafter, alveolar macrophage accumulation in the irradiated tissue increased, and
TGF-β was dramatically expressed [36]. Macrophages can be divided into two subsets according
to their distinct functions [37–39]. The two subsets are known as classically activated macrophages
(M1 macrophages) and alternatively activated macrophages (M2 macrophages). M1 macrophages are
known to play a primary role in the onset of injury [40–42]. They secrete pro-inflammatory cytokines that
exacerbate damage, amplify the inflammatory response, and contribute to myofibroblast proliferation
and recruitment of fibroblasts [43,44]. M1 macrophages are responsible for the release of matrix
metalloproteinases (MMP) that break down ECM and promote EMT/EndMT [45], and M2 macrophages
contribute to the control of inflammatory processes [46]. When the acute phase of inflammation
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is complete, Th2 cytokines are produced, which promote the polarization and recruitment of M2
macrophages [47]. In addition, M2 macrophages create an anti-inflammatory environment and promote
wound healing [48] and regeneration [49]. However, in the lesion, M2 macrophages may play an
important role in the pro-fibrotic process by secreting large amounts of pro-fibrotic factors [50] (Table 1).
4.1. Cytokine Responses in RIPF
Since various cytokines affect the particular processes of RIPF [51], cytokines have been intensively
studied as signaling molecules related to the RILI process and as candidate biomarkers that can
identify the risk of RIPF development. Although each cytokine has a unique expression profile,
within 4–24 h after irradiation, there is often a nonspecific acute reaction (so-called ‘cytokine storm’)
characterized by elevated expression of numerous cytokines. This is followed by a decrease in cytokine
levels to baseline within a period of 24 h to a few days [52]. Hundreds of studies have examined the
expression of cytokines after irradiation, and a wide spectrum of cytokine profiles are available for
both patients and animal models. Damaged pneumocytes, resident macrophages, and endothelial cells
release inflammatory cytokines such as TGF-β (Transforming growth factor-β), TNFα (Tumor necrosis
factor-α), PDGF (platelet-derived growth factor), IL-1 (Interleukin-1) and IL-6 (Interleukin-6) as well as
FGF (Fibroblast growth factor) [31,53–56]. The characteristic changes in the expression of local and
systemic cytokines as well as chemokines are associated with the recruitment of immune cells [57].
Additional studies are necessary to define how the various cells interact and are coordinated during
irradiation-induced pulmonary injury (Table 2).
Table 1. Related cells in the development of radiation-induced pulmonary fibrosis (RIPF).
Classification Characteristics Reference
Alveolar epithelial cells and
vascular endothelial cells
− Connection between these cells are damaged by IR 1, causing
RIPF 2 due to dysregulation of myofibroblasts and excessive
extracellular matrix (ECM) deposition
[58]
Fibroblast
− Its accumulation by IR is mediated by TGF-β1 3, TGF-α1 4,





− Existence predominantly within injured regions
− Injury exacerbration and amplification of inflammatory
response with pre-inflammatory cytokine release
− Recruitment of fibroblasts and promote to
myofibroblasts proliferation
− Involvement of MMP (Matrix metalloproteinase) release that




− Involvement of an anti-inflammatory environment and wound
healing promotion
− Important pro-fibrotic role in the persistent injured lesion
− Secretion of large amounts of profibrotic factors (TGF-β
and galactin-3)
Th1 and Th2 cells
− Important role in the development of RIPF
− Th1 8 mainly contributes to acute radiation pneumonitis, and
Th2 mainly contributes to chronic RIPF.
[59]
1 IR: irradiation; 2 RIPF: radiation-induced pulmonary fibrosis; 3 TGF-β1:Transforming growth factor beta 1;
4 TGF-α1: Transforming growth factor alpha 1; 5 PDGF: Platelet-derived growth factor; 6 CXCL12: C-X-C motif
chemokine ligand 12; 7 ECM: Extracellular matrix; 8 Th1: T helper type 1.
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Table 2. Cytokines in the development of RIPF.
Name Cells of Origin Characteristics Ref.
CCL2/MCP-1 1 Macrophages,
epithelium
− Monocyte chemo-attractant protein
[60]









− Promotes vasoconstriction, stimulates ECM 4
production in fibroblasts [61]
IFN-γ 5 Th1 cells
(Type I helper cell)
− Involvement in inhibition of IL-4, IL-13, and
TGF-β1-related pathways
[62]
− Inhibition of Th2 cell differentiation and
Th2-derived cytokines expression
IL-1β 6 Monocytes, macrophages
− One of the strong pro-inflammatory cytokines
[63,64]
− Induction and propagation of inflammation
IL-13 7 T cells
(Thy-2 CD34+)
− Important pro-fibrotic cytokines and closely
related with fibrosis of lung
[65,66]
− Similar function to IL-4 (because of sharing the α
chain of the IL-4 receptor)
IL-4 8 T cells
(Thy-2 CD34+)
− Important role in the adaptive immune response
[67–70]






− Major regulator involved in the survival,
differentiation, and proliferation of
monocytes/macrophages [29]





− PDGFR-α 11 is related to fibrosis and
transactivated by TGFβ1
[33,59,71]
− Stimulation of the myofibroblast proliferation and
the ECM synthesis via PDGF (platelet-derived






− Converting fibroblast into
matrix-producing myofibroblast
[33,58]
− Promotes synthesis of collagen and inhibits
synthesis of collagenase and plasminogen activator
TNF-α 13 Activated T cells,
macrophages
− Induction of NF-κB activity
[72–74]
− Regulation of immunity and inflammatory
gene expression
1 CCL2 /MCP-1: C-C motif chemokine ligand 2/Monocyte chemoattractant protein 1; 2 CCL3/MCP-2: C-C motif
chemokine ligand 3/Monocyte chemoattractant protein 2; 3 ET-1: Endothelin 1; 4 ECM: Extracellular matrix; 5 IFN-γ:
Interferon gamma; 6 IL-1β: Interleukin 1 beta; 7 IL-13: Interleukin 13; 8 IL-4: Interleukin 4; 9 M-CSF: Macrophage
colony stimulating factor; 10 PDGF: Platelet-derived growth factor; 11 PDGFR-α: Platelet-derived growth factor
receptor-α; 12 TGF-β: Transforming growth factor- β; 13 TNF-α: Tumor necrosis factor- α.
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4.2. EMT (Epithelial-Mesenchymal Transition) in RIPF
IR induced a series of complex injuries mediated by oxidative stress, cell death, senescence,
and loss of normal lung barrier functions [75]. Some alveolar epithelial cells may undergo EMT and
EMT is controlled by transcription factors such as Snail and Twist. Activation of these transcription
factors inhibits E-cadherin and increases the expression of contractile protein α-SMA (Smooth muscle
actin) [76–79]. The EMT associated with wound healing, tissue regeneration, and organ fibrosis is
considered a second type of EMT. Type 2 EMT generally initiates the production of fibroblasts and
other related cells to reconstruct tissues after trauma and inflammatory injury [80]. The production
of numerous molecules by inflammatory cells and resident myofibroblasts is associated with Type 2
EMT. These molecules destroy the epithelial layer through the breakdown of the basement membrane.
The loss of epithelial cells polarity induces apoptosis or EMT [17]. However, unlike to type 1 EMT, type
2 EMT is associated with inflammation and stops when inflammation is weakened during processes
of wound healing and tissue regeneration. The combination of sustained myofibroblast activation,
collagen deposition, EMT, and sustained activation of inflammatory cytokine signaling is likely to lead
to fibrosis and collagen produced primarily by fibroblasts. This collagen is the most abundant matrix
in fibrotic lesions.
5. Therapeutic Targets and Their Inhibitors in RIPF
5.1. Inflammatory Cells
The therapeutic strategy for treating lung injury after IR is restoring the immunological balance.
With this treatment strategy, corticosteroids play a major role in managing acute IR pneumonitis,
but its role in advanced lung fibrosis remains unclear. Inhibition of neutrophil elastase (NE) prevents
the development of lung fibrosis after acute lung injury [81]. Irradiated mice that received sivelestat
survived longer than mice that received IR alone. Sivelestat reduced RIPF in mice by suppressing
NE activity and an excessive inflammatory reaction [82]. CSF1/CSF1R (colony-stimulating factor
receptor-1) pathway is a novel therapeutic candidate for RIPF inhibition based on the results from a
preclinical mouse model following thorax IR and also from using human lung biopsies from patients
who underwent thorax irradiation. The murine counterpart of the human CS4 antibody known as
the anti-CSF1R antibody (CS7) is currently in clinical trials for treating prostate and breast cancer [83].
Specific depletion of infiltrating macrophages in RIPF with CSF1R mAb had an anti-fibrotic effect, and
CSF1R was identified as a potent antifibrotic target [84]. Navitoclax (ABT-263), a B cell lymphoma
2/extra-large (Bcl-2/xl) inhibitor, and a newly identified senolytic drug can reverse RIPF even at the late
stages of fibrosis [85]. This finding suggests that ABT-263 is a potentially effective treatment for RIPF.
5.2. ROS (Reactive Oxygen Species)
The thiophosphate, amifostine, is the only agent approved by the FDA as a clinical IR protector
and its active metabolite acts as a radical scavenger [52] to protect against lung and soft tissue fibrosis.
Mammary adenocarcinoma bearing rats that received fractionated RT and were treated with amifostine
showed reduced lung damage with low plasma TGF-β levels. In addition, administration of amifostine
before IR also reduced macrophage accumulation and TGF-β1 expression in lung tissue [86]. Superoxide
dismutase (SOD) is a metalloprotease that protects against oxidative damage [36]. Recombinant
SOD-TAT (Superoxide dismutase fusion of TAT) protein protected against RILI in mice. When
irradiated mice were examined after pretreatment with SOD-TAT, improved growth rate and reduced
lung hydroxyproline content as well as sustained SOD activity, glutathione peroxide (GSH-Px) activity,
and total antioxidant capacity were detected [87].
5.3. Cytokines/Chemokines
Toll-like receptor (TLR) activation requires a number of intracellular adaptor proteins proximal to
TLR and the most prominent one is a myeloid differentiation primary response factor 88 (MyD88).
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MyD88 contains two prominent domains, a TLR/IL1 receptor domain, and a death domain. MyD88 is
a key control factor for innate immune signaling by pathogenic and environmental stresses. MyD88
regulates innate immunity, reduces long-term RILI, and alleviates fibrosis development by preventing
chronic lung damage [29,88]. Activation of the chemokine receptor CXCR4 by its ligand stromal
cell-derived factor 1 (SDF-1/CXCL12) may also involve the development of RIPF [89]. MSX-122 is a
novel small molecule and partial inhibitor of CXCR4, and the CXCR4/CXCL12 axis has been shown to
be critical for the development of RIPF in a mouse model. CXCR4 inhibition by MSX-122 may alleviate
potential RILI, which represents a therapeutic opportunity for patients requiring chest irradiation [89].
5.4. TGF-β (Transforming Growth Factor-β)
Activation of the TGF-β/Smad signaling pathway, which is an important step for fibrosis
development, has been explored as a potential intervention strategy. SM16, a small molecule
inhibitor of the TGF-β receptor I, reduced the degree of RILI in a rat model [29]. Rats that received
SM16 experienced a significant decrease in PF, inflammatory response, and TGF-β1 activity [90].
LY2109761 is a novel small-molecule TGF-β receptor I serine/threonine kinase inhibitor that markedly
reduces inflammation and PF by IR, which results in prolonged survival. This inhibitor directly
attenuates profibrotic signaling pathways as well as mediates TGF-β/bone morphogenetic protein
(BMP) signaling [91]. Galunisertib is a highly selective inhibitor of TGF-β receptor I by complete
inhibition of its phosphorylation and activation [92]. Treatment with galunisertib attenuated IR-induced
pulmonary inflammation and fibrosis. SB203580 and WP631 inhibited the Smad signal transduction
pathway, abrogated excessive proliferation, and reduced the expression of p21 (WAF1/CIP1) and
PAI-1 (Plasminogen Activator inhibitor-1) induced by IR and TGF-β1 [29]. SB203580, which is a
pyridinylimidazole, can highly and specifically inhibit TGF-β receptor I. WP631, which is a serine
proteinase inhibitor, inhibited the expression of PAI-1. An increase in expression and activation of PAI-1
could effectively prevent hydrolysis of fibrous proteins and degradation of the ECM, which causes the
precipitation of fibrous proteins within tissues and the accumulation of ECM [93]. Thalidomide was
shown to inhibit TGF-β1-induced α-SMA and vimentin production as well as pulmonary epithelial cell
morphological changes by suppressing both Smad-dependent and non-Smad-dependent pathways.
Thus, thalidomide may have potential as a therapeutic agent to inhibit pulmonary fibrosis [89].
5.5. PDGF (Platelet-Derived Growth Factor)
The platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitors significantly
attenuate the development of fibroblast foci, characteristics of PF, and subsequent remodeling of the
pulmonary structure. SU9518 is a highly selective inhibitor of the PDGF receptors α and β, which
blocks PDGF receptor kinase activity and PDGF receptor-induced cell proliferation [36]. SU9518,
SU1167, and imatinib mesylate with all activity against PDGF receptor α and PDGF receptor β have
been shown to attenuate PF in an animal model [94]. SU9518 treatment significantly reduced collagen
deposition, alveolar wall thickness, and other histological signs of fibrosis [95,96].
5.6. CTGF (Connective Tissue Growth Factor)
Connective tissue growth factor (CTGF) is known as a molecule for TGF-β-mediated fibrosis.
However, CTGF, once activated, has been reported to promote and maintain PF by exerting a direct
fibrosis effect out of control by TGF-β. This hypothesis is supported by data demonstrating that CTGF
activates collagen type 1 and promotes ECM synthesis. CTGF depletion in fibroblasts and smooth
muscle cells significantly reduced fibrosis [97]. Pamrevlumab (FG-3019), which is a human monoclonal
antibody against CTGF, exhibits reprogrammed fibrogenesis through normalization of IR-induced
genes. These genes regulate inflammation associated with M2 macrophage influx, EMT, myofibroblast
activation, tissue remodeling, and ECM deposition. Treatment of FG-3019 to irradiated mice reversed
lung regeneration, preserved lung function, and increased survival [36,98,99].
Cancers 2020, 12, 1561 10 of 23
5.7. Miscellaneous Targets
The renin-angiotensin system is known to regulate blood pressure and fluid balance and has
also been reported to be involved in the development of RILI. Some angiotensin-converting enzyme
(ACE) inhibitors have proven to protect the lungs from fibrosis after IR exposure [97]. Treatment of
three structurally different ACE inhibitors (fosinopril, captopril, and enalapril) in drinking water after
whole thorax IR reduced collagen synthesis [100]. Methoxystradiol (2-ME), which is a metabolite of
17-beta-estradiol, has been proposed to effectively inhibit HIF-1α. 2-ME suppressed the IR-induced
increase of HIF-1α (Hypoxia-inducible factor 1 alpha), which led to a decreased EndMT. The deposition
of vascular collagen during RIPF development was also inhibited [33,36]. Myriocin is a specific inhibitor
of serine palmitoyltransferase (SPT) and can block the de novo biosynthesis of sphingolipids. Targeting
SPT with myriocin can counteract TGF-β–mediated signaling and RIPF progression, suggesting that
SPT may be a novel therapeutic target for managing RIPF [36,101]. IR of the lung is associated with
increased IL-4 expression and that of its receptor, IL4 receptor α1, as well as the dual oxidase 2 (DUOX2)
gene. Treatment with metformin suppressed upregulation of IR-induced genes and IL-4, which was
associated with amelioration of pathological changes. Treatment with metformin attenuated the
upregulation of the IL-4–DUOX2 pathway and other pathological damages to the lung after exposure
to a high dose of IR [102]. The heat shock protein 27 (HSP27) was also identified as a candidate target
for treating PF in a mouse model of clinical SBRT. Inhibition of HSP27 using a recently identified
small-molecule inhibitor, J2, induces crosslinking of HSP27 attenuated RIPF development. Mechanism
underlying HSP27-mediated fibrosis development is IkBa-NFkB signaling activation, which is involved
in the EMT process (Table 3) [103].
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Table 3. Therapeutic targets for radiation-induced pulmonary fibrosis (RIPF).
Name Structure Target Mode of Action Clinical Trials andNCT Number
Glucocorticosteroid Inflammatory cells
− Main management in acute IR pneumonitis
− Not clear in PF
− Induce side effects on long-term use
Sivelestat Neutrophil elastase
− Neutrophil elastase inhibitor
− Decrease of collagen deposition and accumulation
of neutrophils
− Inhibition of RILI in mice





− Depletion of IM in RIPF model→Reverse PF




− A specific Bcl-2/xl inhibitor and a senolytic drug
− Reverse PF after thoracic IR in mice model Research
BBT-877 Autotaxin (ATX) − Autotaxin inhibitor Phase 1, NCT03830125(completed)
GLPG1690 Autotaxin (ATX) − Autotaxin inhibitor Phase 2, NCT02738801(completed)
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Table 3. Cont.
Name Structure Target Mode of Action Clinical Trials andNCT Number
GLPG1205 GPR84 − Specific GPR84 inhibitor Phase 2, NCT03725852(Active)
PBI-4050 GPR40 and GPR84
− Activation of GPR40 receptor Phase 2, NCT02538536
(completed)
− Suppression of GPR84 activity
BMS-986020 Lysophosphatidic acid(LPA) receptor




− Repurposing of circulatory drug




PXS-5382A LOXL2 − LOXL2 inhibitor Research
PAT-1251 LOXL2 − LOXL2 inhibitor Research
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Table 3. Cont.





− Inhibition of Rho-associated coiled-coil kinase or ROCK2 Phase 2,
NCT02688647(active)
BLD-2660 Calpain − Calpain inhibitor Phase 2, NCT04244825(Not yet recruiting)
Pamrevlumab CTGF (ConnectiveTissue Growth Factor)
− Recombinant human monoclonal antibody
− CTGF inhibitor
− Restoring lung function in the mouse model
− Inhibition of M2 polarized macrophage influx and
myofibroblast abundance




− PDGFR tyrosine kinase inhibitor
− Inhibition of collagen deposition, alveolar wall thickness,
and other histologically visible signs of fibrosis in a
mouse model
− Inhibition of IR-induced fibroblast and endothelial
cell activation
Research
SU11657 PDGF − PDGFR tyrosine kinase inhibitor Research
Imatinib PDGF
− Inhibitor of tyrosine kinases of the TGFβ and
PDGF pathways
− Inhibition of RIPF in a mouse model
Phase 1, NCT03328117
(completed)
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Table 3. Cont.
Name Structure Target Mode of Action Clinical Trials andNCT Number
Pirfenidone Multiple targets − Inhibition of TGF-β, TNF, IL-10, p38α and p38γ, and p38α Clinical use
Thalidomide TGF-β1
− Inhibition of TGF-β1-induced α-SMA and vimentin
production and TGF-β1-induced cell morphological




SM16 TGF-β RI − TGF-β RI inhibitor Research
LY2109761 TGF-βRI/II − Dual inhibitor of TGF-β RI/II Research
Galunisertib TGF-β RI − Highly selective TGF-β RI inhibitor Research
SB203580 TGF-β RI
− TGF-β RIkinase inhibitor
− Inhibitor of TGF-β/Smad signal transduction Research
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Table 3. Cont.
Name Structure Target Mode of Action Clinical Trials andNCT Number
WP631 TGF-β/Smad
− DNA intercalator
− Inhibitor of TGF-β/Smad signal transduction
− Inhibition of PAI-1
Research
MyD88 Recombinant protein
− A key intracellular adaptor of TLR signaling
− Involving innate immunity and NF-κB activation responses
− Absence of MyD88 results in unresolved pulmonary
infiltrates and enhanced collagen deposition
Research
MSX-122 CXCR4
− A novel small molecule and partial CXCR4 antagonist
− CXCR4/CXCL12-axis is critical in the development of RIPF
in a mouse model
− Reduces RIPF
Research
PLN-74809 Integrin αvβ6, αvβ1 − Selective inhibitor of the αvβ6 and αvβ1 integrins Phase 2, NCT04072315(recruiting)
IDL-2965 Integrin αvβ1, αvβ3,
and αvβ6
− Inhibitor of three integrin αvβ1, αvβ3, and αvβ6
Phase 1, NCT03949530
(recruiting)
− Blocks the activation of TGF-β
PRM-151 Amyloid P/Pentraxin 2protein
− A recombinant human serum amyloid P/Pentraxin 2 protein Phase 2, NCT02550873
(active)
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Table 3. Cont.





− Inhibitor of PI3K and mTOR signals Phase 1, NCT01725139
(completed)
Nintedanib Clinical use
Amifostine Reactive oxygenspecies (ROS)
− Active metabolite scavenger of ROS
− Radioprotector approved by FDA
− Inhibition of plasma level of TGF-β




− Pretreatment enhances antioxidant ability and reduced






− Inhibition of HIF-α
− Inhibition of EndMT and deposition of vascular collagen Research
Myriocin SPT
− Inhibitor of serine palmitoyl transferase (SPT)
− Inhibition of de novo biosynthesis of sphingolipids Research
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Table 3. Cont.
Name Structure Target Mode of Action Clinical Trials andNCT Number
Metformin
− Inhibition of IL-4-DUOX2 pathway
− Inhibition of infiltration of macrophages and lymphocytes Research
ACE inhibitors
− Inhibition of morbidity during the pneumonitis phase
− Inhibition of RIPF in the mouse model Research
Abbreviations: IR: Irradiation; PF: Pulmonary fibrosis; RILI: Radiation-induced lung injury; IM: Interstitial macrophage; PDGFR: Platelet-derived growth factor receptor; IL: Interleukin;
TGF-β: Transforming growth factor-β; TNF: Tumor necrosis factor; PAI-1: Plasminogen Activator inhibitor-1; TLR: Toll-like receptor; SOD-TAT: Superoxide dismutase fusion of TAT; ROS:
Reactive oxygen species; HIF-1α: Hypoxia-inducible factor 1 alpha.* Clinical trials and NCT number: https://www.clinicaltrials.gov/ct2/home.
Cancers 2020, 12, 1561 18 of 23
6. Conclusions
Tolerance of lung tissue to IR and subsequent development of IR pneumonitis and fibrosis limit
the effectiveness of RT. However, despite the urgent need for improved treatment of RIPF, there are
no clinically used methods for RIPF treatment. In addition to drug development, it is important to
identify the predictive biomarker that can help identify patients susceptible to RIPF, so that a lower IR
dose can be administered to these patients. Future research efforts should focus on identifying novel
RIPF inhibitors to improve the treatment of patients with RIPF. Combining small animal irradiators
with appropriate animal models and preclinical molecular and functional imaging studies has great
potential to further enhance our understanding of the IR response of lung tissue. This approach
may help address long-standing questions about the inter-relationships of acute and late effects of
IR. This will further promote the development of effective novel treatments that can preserve lung
function and quality of life after RT.
In this review, we emphasized the importance of small animal models that can mimic SBRT in
terms of delivering high-dose focal irradiation. Regarding the level of vascular dysfunction in the lung
tissue, it may occur after high-dose IR. Additional mechanisms are significantly affected in normal
tissues after SBRT when compared to conventional RT. However, due to the limited understanding of
basic mechanisms and the quantitative impact of clinical outcomes, many questions and investigations
are needed to alleviate the effects of high-dose radiation on lung injury. Therefore, more examination
using additional animal models are needed.
In conclusion, recent advances have led to the development of more persistent experimental RIPF
models and have allowed investigation of targeted epithelial damage, fibroblast-specific alterations,
regulation of inflammatory cells during fibrosis, and epithelial-mesenchymal crosstalk. Although these
models are still unable to replicate all the features of human RIPF pathology, specific analysis of signal
pathways and interaction analysis among various cell types may be possible. More persistent models
can enhance our ability to study mechanisms that are operative during the fibrogenic stage, which will
increase the likelihood of translating the animal model findings to human disease and facilitate the
assessment of therapeutic efficacy on fibrotic remodeling. This may enable a more precise prediction of
which compounds have the ability to improve results after fibrosis is established.
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